Dose-dense oxaliplatin + Irinotecan 	Oxaliplatin 	Time until definitive deterioration of insomnia	1496	1627	Cox multivariate analysis showed no statistically significant difference in TUDD for most of the QLQ-C30 scales between treatments.
Dose-dense oxaliplatin + Irinotecan 	Oxaliplatin 	Time until definitive deterioration of pain	1496	1627	Cox multivariate analysis showed no statistically significant difference in TUDD for most of the QLQ-C30 scales between treatments.
Dose-dense oxaliplatin + Irinotecan 	Oxaliplatin 	Time until definitive deterioration of fatigue	20603	20787	Multivariate Cox analyses (Fig 4 and S3 Table) showed no statistically significant difference in TUDD for the studied scales of the QLQ-C30 between treatments, except three dimensions.
Dose-dense oxaliplatin + Irinotecan 	Oxaliplatin 	Time until definitive deterioration of fatigue	20046	20200	The results of univariate Cox regression analysis of TUDD (Fig 2) showed no statistically significant difference between treatments for the studied scales
Dose-dense oxaliplatin + Irinotecan 	Oxaliplatin 	Time until definitive deterioration of Nausea/vomiting	20603	20787	Multivariate Cox analyses (Fig 4 and S3 Table) showed no statistically significant difference in TUDD for the studied scales of the QLQ-C30 between treatments, except three dimensions.
Dose-dense oxaliplatin + Irinotecan 	Oxaliplatin 	Time until definitive deterioration of insomnia	20603	20787	Multivariate Cox analyses (Fig 4 and S3 Table) showed no statistically significant difference in TUDD for the studied scales of the QLQ-C30 between treatments, except three dimensions.
Dose-dense oxaliplatin + Irinotecan 	Oxaliplatin 	Global health status time until definitive deterioration 	20337	20592	For example, for GHS score, the median TTD was 13.4 months (95% IC: 6.6–19.4) for patients treated with FOLFOX4 (n = 37) and 20 months (95% IC: 6.6–26.3) for patients treated with FOLFOX7-FOLFIRI (n = 46; Fig 3A), with the univariate HR of 0.95 [0.61–1.47
